AddriÃ¡n Llerena

List of Publications by Year
in descending order

161	4,556	94433 37	133252 59
papers	citations	h-index	g-index

172	172	172	3800
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.. British Journal of Clinical Pharmacology, 1994, 38, 471-473.	2.4	245
2	Haloperidol Disposition Is Dependent on Debrisoquine Hydroxylation Phenotype. Therapeutic Drug Monitoring, 1992, 14, 92-97.	2.0	174
3	Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clinical Pharmacology and Therapeutics, 2002, 71, 89-98.	4.7	164
4	Relationship between personality and debrisoquine hydroxylation capacity. Acta Psychiatrica Scandinavica, 1993, 87, 23-28.	4.5	152
5	Interethnic variability ofCYP2D6alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1569-1583.	3.3	129
6	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	3.3	107
7	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLAâ€B Genotypes and Phenytoin Dosing: 2020 Update. Clinical Pharmacology and Therapeutics, 2021, 109, 302-309.	4.7	102
8	Haloperidol Disposition Is Dependent on the Debrisoquine Hydroxylation Phenotype. Therapeutic Drug Monitoring, 1992, 14, 261-264.	2.0	99
9	Criterios de valoraciÃ³n clÃnicos y de funcionamiento en un estudio de interacciÃ³n gen-ambiente en primeros episodios psicÃ³ticos (PEPs). Revista De PsiquiatrÃa Y Salud Mental, 2013, 6, 4-16.	1.8	99
10	CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. European Journal of Clinical Pharmacology, 2003, 59, 221-225.	1.9	95
11	Disposition of clozapine in man: lack of association with debrisoquine and Sâ€mephenytoin hydroxylation polymorphisms.. British Journal of Clinical Pharmacology, 1994, 37, 71-74.	2.4	87
12	Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. European Journal of Clinical Pharmacology, 2004, 59, 869-873.	1.9	69
13	QTc Interval, CYP2D6 and CYP2C9 Genotypes and Risperidone Plasma Concentrations. Journal of Psychopharmacology, 2004, 18, 189-193.	4.0	69
14	Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. BioTechniques, 2005, 39, S571-S574.	1.8	68
15	Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics, 2008, 9, 833-840.	1.3	66
16	Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics, 2009, 10, 17-28.	1.3	65
17	Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clinical Pharmacology and Therapeutics, 1993, 54, 606-611.	4.7	58
18	QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. Journal of Psychopharmacology, 2002, 16, 361-364.	4.0	58

#	Article	IF	Citations
19	CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics, 2007, 8, 1597-1608.	1.3	58
20	Pharmacokinetic Interaction of Fluvoxamine and Thioridazine in Schizophrenic Patients. Journal of Clinical Psychopharmacology, 1999, 19, 494-499.	1.4	58
21	Debrisoquin oxidation polymorphism in a Spanish population. Clinical Pharmacology and Therapeutics, 1988, 44, 74-76.	4.7	54
22	Toward More Transparent and Reproducible Omics Studies Through a Common Metadata Checklist and Data Publications. OMICS A Journal of Integrative Biology, 2014, 18, 10-14.	2.0	54
23	Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.. British Journal of Clinical Pharmacology, 1995, 40, 467-476.	2.4	53
24	A PVCâ€“graphite composite electrode for electroanalytical use. Preparation and some applications. Analytica Chimica Acta, 1997, 355, 23-32.	5.4	53
25	Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 783, 25-31.	2.3	52
26	Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. Schizophrenia Research, 2018, 193, 188-196.	2.0	50
27	Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics, 2009, 10, 1111-1120.	1.3	49
28	Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1893-1905.	3.3	49
29	Effect of Thioridazine Dosage on the Debrisoquine Hydroxylation Phenotype in Psychiatric Patients With Different CYP2D6 Genotypes. Therapeutic Drug Monitoring, 2001, 23, 616-620.	2.0	48
30	Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clinical Pharmacology and Therapeutics, 1989, 45, 328-333.	4.7	46
31	Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. European Journal of Clinical Pharmacology, 2003, 59, 45-50.	1.9	46
32	Schizophrenia stigma among medical and nursing undergraduates. European Psychiatry, 2002, 17, 298-299.	0.2	43
33	<scp>CYP2D6</scp> variation, behaviour and psychopathology: implications for pharmacogenomicsâ€guided clinical trials. British Journal of Clinical Pharmacology, 2014, 77, 673-683.	2.4	42
34	The Underlying Traits of the Karolinska Scales of Personality (KSP). European Journal of Psychological Assessment, 2002, 18, 139-148.	3.0	42
35	Success stories in genomic medicine from resource-limited countries. Human Genomics, 2015, 9, 11.	2.9	41
36	Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 783, 213-219.	2.3	40

#	Article	IF	Citations
37	Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment. Molecular Psychiatry, 2017, 22, 1155-1163.	7.9	39
38	CYP450 genotype and pharmacogenetic association studies: a critical appraisal. Pharmacogenomics, 2016, 17, 259-275.	1.3	38
39	Use of the Mesoridazine/Thioridazine Ratio as a Marker for CYP2D6 Enzyme Activity. Therapeutic Drug Monitoring, 2000, 22, 397-401.	2.0	38
40	CYP2D6 and the severity of suicide attempts. Pharmacogenomics, 2012, 13, 179-184.	1.3	37
41	Pharmacogenetics of clinical response to risperidone. Pharmacogenomics, 2013, 14, 177-194.	1.3	36
42	CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for costâ€“effectiveness studies. Pharmacogenomics, 2009, 10, 685-699.	1.3	34
43	Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers. Drug Metabolism and Drug Interactions, 2014, 29, 129-141.	0.3	34
44	Schizophrenia and tobacco smoking in a Spanish psychiatric hospital. Schizophrenia Research, 2003, 60, 313-317.	2.0	32
45	Influence of CYP2D6 Deletion, Multiplication, â€“1584Câ†'G, 31Gâ†'A and 2988Gâ†'A Gene Polymorphisms on Dextromethorphan Metabolism among Mexican Tepehuanos and Mestizos. Pharmacology, 2010, 86, 30-36.	2.2	32
46	Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics. OMICS A Journal of Integrative Biology, 2018, 22, 575-588.	2.0	32
47	Ready to Put Metadata on the Post-2015 Development Agenda? Linking Data Publications to Responsible Innovation and Science Diplomacy. OMICS A Journal of Integrative Biology, 2014, 18, 1-9.	2.0	31
48	A rapid and simple LCâ€“MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity. Bioanalysis, 2014, 6, 683-696.	1.5	31
49	To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotypeâ€“Phenotype Concordance and Discordance in the Ecuadorian Population. OMICS A Journal of Integrative Biology, 2016, 20, 699-710.	2.0	31
50	CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populationsâ€“Where to from Here for Global Precision Medicine?. OMICS A Journal of Integrative Biology, 2017, 21, 509-519.	2.0	30
51	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. International Journal of Neuropsychopharmacology, 2016, 19, pyv121.	2.1	29
52	Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender. Pharmacogenomics, 2012, 13, 1711-1717.	1.3	28
53	CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico. Pharmacogenomics, 2014, 15, 339-348.	1.3	28
54	Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach. Current Pharmaceutical Biotechnology, 2016, 17, 1159-1180.	1.6	28

#	Article	IF	Citations
55	Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: Analyses of mutations on NAT2 and CYP2E1 genes in a mixed Hispanic population*. Clinical Pharmacology and Therapeutics, 1998, 63, 623-628.	4.7	27
56	CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. European Journal of Clinical Pharmacology, 2012, 68, 637-644.	1.9	27
57	Genomic Ancestry, <scp>CYP</scp>2D6, <scp>CYP</scp>2C9, and <scp>CYP</scp>2C19 Among Latin Americans. Clinical Pharmacology and Therapeutics, 2020, 107, 257-268.	4.7	27
58	CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenetics and Genomics, 2013, 23, 627-630.	1.5	25
59	The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans. Journal of Clinical Psychopharmacology, 2015, 35, 694-699.	1.4	25
60	Genetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative. Pharmacogenomics Journal, 2018, 18, 749-759.	2.0	25
61	Molecular heterogeneity at the CYP2D gene locus in Nicaraguans: impact of gene-flow from Europe. Pharmacogenetics and Genomics, 1997, 7, 337-340.	5.7	23
62	Association between T102C and Aâ€“1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs. Clinical Chemistry and Laboratory Medicine, 2007, 45, 835-8.	2.3	23
63	CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers. Pharmacogenomics, 2013, 14, 1973-1977.	1.3	23
64	Multiplex Phenotyping for Systems Medicine: A One-Point Optimized Practical Sampling Strategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 Activities Using a Cocktail Approach. OMICS A Journal of Integrative Biology, 2016, 20, 88-96.	2.0	23
65	Reduced completed suicide rate in Hungary from 1990 to 2001: Relation to suicide methods. Journal of Affective Disorders, 2005, 88, 235-238.	4.1	22
66	Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine. Drug Metabolism and Drug Interactions, 2011, 26, 5-12.	0.3	22
67	Polymorphic Oxidation of Debrisoquine in Women with Breast Cancer. Oncology, 1991, 48, 107-110.	1.9	21
68	Polymorphic oxidation of debrisoquine in lung cancer patients. European Journal of Cancer & Clinical Oncology, 1991, 27, 158-161.	0.7	20
69	Analysis of diclofenac and its metabolites by high-performance liquid chromatography: relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 789, 437-442.	2.3	20
70	Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism. OMICS A Journal of Integrative Biology, 2017, 21, 17-26.	2.0	20
71	Therapeutic Drug Monitoring of Fluoxetine, Norfluoxetine and Paroxetine: A New Tool Based on Microextraction by Packed Sorbent Coupled to Liquid Chromatography. Journal of Analytical Toxicology, 2017, 41, 631-638.	2.8	20
72	Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations. Scientific Reports, 2018, 8, 12726.	3.3	20

#	Article	IF	Citations
73	Determination of clozapine and its N-desmethyl metabolite by high-performance liquid chromatography with ultraviolet detection. Biomedical Applications, 2001, 755, 349-354.	1.7	18
74	QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy. European Journal of Clinical Pharmacology, 2002, 58, 223-224.	1.9	18
75	Relationship between Haloperidol Plasma Concentration, Debrisoquine Metabolic Ratio,CYP2D6andCYP2C9Genotypes in Psychiatric Patients. Pharmacopsychiatry, 2004, 37, 69-73.	3.3	18
76	Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations. Molecular Biology Reports, 2013, 40, 3187-3192.	2.3	18
77	Antipsychotic drugs and QTc prolongation: the potential role ofCYP2D6genetic polymorphism. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 9-19.	3.3	17
78	Relevance of CYP2D6-1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients. Pharmacogenomics, 2009, 10, 1083-1089.	1.3	17
79	Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics, 2012, 13, 1773-1782.	1.3	17
80	Interethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: a report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics). Drug Metabolism and Personalized Therapy, 2016, 31, 61-81.	0.6	17
81	Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients. European Journal of Clinical Pharmacology, 2008, 64, 73-76.	1.9	16
82	Present status and perspective of pharmacogenetics in Mexico. Drug Metabolism and Drug Interactions, 2014, 29, 37-45.	0.3	16
83	Pharmacogenetics in Central American healthy volunteers: interethnic variability. Drug Metabolism and Personalized Therapy, 2015, 30, 19-31.	0.6	16
84	ATA homozigosity in the IL-10gene promoter is a risk factor for schizophrenia in Spanish females: a case control study. BMC Medical Genetics, 2011, 12, 81.	2.1	15
85	Cytochrome P450 genetic polymorphisms of Mexican indigenous populations. Drug Metabolism and Drug Interactions, 2013, 28, 193-208.	0.3	15
86	Relationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers. Pharmacogenomics, 2014, 15, 1417-1421.	1.3	15
87	Pharmacogenomics in pain treatment. Drug Metabolism and Personalized Therapy, 2016, 31, 131-142.	0.6	15
88	Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans. Revista De Biologia Tropical, 2014, 62, 1659.	0.4	15
89	Subtyping undergraduate women along dietary restraint and negative affect. Appetite, 2008, 51, 727-730.	3.7	14
90	A Code of Ethics for Ethicists: What Would Pierre Bourdieu Say? â€œDo Not Misuse Social Capital in the Age of Consortia Ethicsâ€• American Journal of Bioethics, 2015, 15, 64-67.	0.9	14

#	Article	IF	Citations
91	An Appeal to the Global Health Community for a Tripartite Innovation: An â€œEssential Diagnostics List,â€• â€œHealth in All Policies,â€•and â€œSee-Through 21st Century Science and Ethicsâ€• OMICS A Journal of Integrative Biology, 2015, 19, 435-442.	2.0	14
92	Pharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America. Pharmacogenomics, 2016, 17, 1741-1747.	1.3	14
93	Polymorphic Oxidation of Debrisoquine in Bladder Cancer. Annals of Medicine, 1990, 22, 157-160.	3.8	13
94	Schizophrenia and tobacco smoking in a Spanish psychiatric hospital. Schizophrenia Research, 2002, 58, 323-327.	2.0	13
95	Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. Clinical Chemistry and Laboratory Medicine, 2005, 43, 275-9.	2.3	13
96	CYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas. Pharmacogenomics, 2014, 15, 1859-1865.	1.3	13
97	Interethnic relationships of CYP2D6 variants in native and Mestizo populations sharing the same ecosystem. Pharmacogenomics, 2015, 16, 703-712.	1.3	13
98	Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. European Neuropsychopharmacology, 2017, 27, 647-656.	0.7	13
99	Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. Pharmacogenomics, 2010, 11, 1619-1625.	1.3	12
100	MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers. Drug Metabolism and Drug Interactions, 2013, 28, 163-166.	0.3	12
101	Progress in pharmacogenetics: consortiums and new strategies. Drug Metabolism and Personalized Therapy, 2016, 31, 17-23.	0.6	12
102	Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population. Pharmacogenomics Journal, 2021, 21, 140-151.	2.0	12
103	Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications. Personalized Medicine, 2013, 10, 709-718.	1.5	11
104	Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail. Drug Metabolism and Drug Interactions, 2013, 28, 135-146.	0.3	11
105	Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen. Drug Metabolism and Personalized Therapy, 2016, 31, 83-90.	0.6	11
106	Clozapine Withdrawal Symptoms after Change to Sertindole in a Schizophrenic Patient. Pharmacopsychiatry, 2000, 33, 42-44.	3.3	10
107	First MEPS/HPLC assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma. Bioanalysis, 2014, 6, 3025-3038.	1.5	10
108	Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population. Revista De Biologia Tropical, 2016, 64, 1067-76.	0.4	10

#	Article	IF	Citations
109	Aripiprazole-Induced Parkinsonism and Its Association With Dopamine and Serotonin Receptor Polymorphisms. Journal of Clinical Psychopharmacology, 2008, 28, 352-353.	1.4	9
110	Liver enzyme abnormalities during antipsychotic treatment: a case report of risperidone-associated hepatotoxicity. Drug Metabolism and Drug Interactions, 2014, 29, 123-126.	0.3	9
111	New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics. Drug Metabolism and Personalized Therapy, 2018, 33, 61-64.	0.6	9
112	Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes. Drug Metabolism and Drug Interactions, 2012, 27, 217-223.	0.3	8
113	Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers. Pharmacogenomics, 2016, 17, 1913-1930.	1.3	8
114	Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis. Journal of Psychopharmacology, 2018, 32, 702-710.	4.0	8
115	Bernard Lerer: Recipient of the 2014 Inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics). OMICS A Journal of Integrative Biology, 2014, 18, 211-221.	2.0	7
116	Population pharmacogenetics and global health. Drug Metabolism and Personalized Therapy, 2015, 30, 73-74.	0.6	7
117	Can the CEIBA Cocktail Designed for Human Cytochrome P450 Enzymes be Used in the Rat for Drug Interaction Studies?. Journal of Pharmacy and Pharmaceutical Sciences, 2016, 19, 520.	2.1	7
118	Pharmacogenetic research activity in Central America and the Caribbean: a systematic review. Pharmacogenomics, 2016, 17, 1707-1724.	1.3	7
119	Development of a new genotyping assay for detection of the BDNF Val66Met polymorphism using melting-curve analysis. Pharmacogenomics, 2009, 10, 989-995.	1.3	6
120	CYP2D6Polymorphism and Mental and Personality Disorders in Suicide Attempters. Journal of Personality Disorders, 2014, 28, 873-883.	1.4	6
121	Translating Biotechnology to Knowledge-Based Innovation, Peace, and Development? Deploy a Science Peace Corpsâ€"An Open Letter to World Leaders. OMICS A Journal of Integrative Biology, 2014, 18, 415-420.	2.0	6
122	Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy. Pharmacogenomics Journal, 2020, 20, 845-856.	2.0	6
123	Reproducibility over Time of Mephenytoin and Debrisoquine Hydroxylation Phenotypes. Basic and Clinical Pharmacology and Toxicology, 1993, 73, 46-48.	0.0	5
124	Fixed combinations of neuroleptics with antidepressants: potential risks and estimation of use.. British Journal of Clinical Pharmacology, 1994, 37, 531-532.	2.4	5
125	High risk of polydipsia and water intoxication in schizophrenia patients. Schizophrenia Research, 2008, 99, 377-378.	2.0	5
126	CYP2D6 genetic polymorphism and psychiatry patientsâ€™ hospitalization period. Biomarkers in Medicine, 2013, 7, 915-916.	1.4	5

#	Article	IF	Citations
127	Toward More Transparent and Reproducible Omics Studies Through a Common Metadata Checklist and Data Publications. Big Data, 2013, 1, 196-201.	3.4	5
128	Multiple adverse drug reactions and genetic polymorphism testing. Medicine (United States), 2017, 96, e8505.	1.0	5
129	Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial. Scientific Reports, 2019, 9, 17833.	3.3	5
130	CYP2D6Polymorphism and Mental and Personality Disorders in Suicide Attempters. Journal of Personality Disorders, 0, , 1-11.	1.4	4
131	A tribute to JosÃ© MarÃa ("Chema") CantÃº. Genetics and Molecular Biology, 2014, 37, 310-314.	1.3	4
132	Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice. Drug Metabolism and Personalized Therapy, 2015, 30, 143-145.	0.6	4
133	Genetic variability of CYP2C9*2 and CYP2C9*3 in seven indigenous groups from Mexico. Pharmacogenomics, 2016, 17, 1881-1889.	1.3	4
134	Frequency of CYP2C9 (*2, *3 and IVS8â€‘109A>T) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin. Biomedical Reports, 2019, 10, 283-295.	2.0	4
135	Current Insights into Interethnic Variability in Testicular Cancers: Population Pharmacogenetics, Clinical Trials, Genetic Basis of Chemotherapy- Induced Toxicities and Molecular Signal Transduction. Current Topics in Medicinal Chemistry, 2020, 20, 1824-1838.	2.1	4
136	Eating Disorder Symptoms and CYP2D6 Variation in Cuban Healthy Females: A Report from the Ibero-American Network of Pharmacogenetics. Current Pharmacogenomics and Personalized Medicine, 2012, 10, 288-292.	0.2	4
137	Population genetics of PDE4B (phosphodiesteraseâ€4B) in neglected Native Americans: Implications for cancer pharmacogenetics. Clinical and Translational Science, 2022, , .	3.1	4
138	No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients. European Journal of Clinical Pharmacology, 2007, 63, 527-528.	1.9	3
139	Pharmacogenomics and Personality: Role of CYP2D6 and Implications for Psychopathology. Advances in Biological Psychiatry, 2010, , 30-45.	0.2	3
140	Impact of cytochrome P450 genes on suicide attempt and risk. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 703-704.	3.2	3
141	Clinical pharmacology of drug metabolism and drug interactions: clinical, interethnical and regulatory aspects. Drug Metabolism and Drug Interactions, 2013, 28, 1-3.	0.3	3
142	Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: the MedeA initiative. Drug Metabolism and Personalized Therapy, 2020, .	0.6	3
143	GENETIC FACTORS IN THE METABOLISM OF HALOPERIDOL.. Clinical Neuropharmacology, 1992, 15, 84A-85A.	0.7	2
144	Reproducibility over time of the urinary diclofenac/4â€²-OH diclofenac ratio among differentCYP2C9 genotypes. European Journal of Drug Metabolism and Pharmacokinetics, 2003, 28, 213-215.	1.6	2

#	Article	IF	Citations
145	Research Highlights. Pharmacogenomics, 2011, 12, 311-313.	1.3	2
146	High-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients. Drug Metabolism and Drug Interactions, 2012, 27, 165-70.	0.3	2
147	Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285. International Journal of Cardiology, 2013, 168, 3057-3058.	1.7	2
148	Water pipe (Shisha, Hookah, Arghile) Smoking and Secondhand Tobacco Smoke Effects on CYP1A2 and CYP2A6 Phenotypes as Measured by Caffeine Urine Test. OMICS A Journal of Integrative Biology, 2017, 21, 177-182.	2.0	2
149	What is the future of pharmacogenomics in pain management?. Pharmacogenomics, 2017, 18, 101-103.	1.3	2
150	Research Highlights: Novel CYP2C9 genetic polymorphisms and assessment of their impact on hydroxylation capacity. Pharmacogenomics, 2014, 15, 261-264.	1.3	1
151	The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. Whatâ€™s next? An urgent clinical unmet need for patients. Drug Metabolism and Personalized Therapy, 2021, .	0.6	1
152	Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: the MedeA initiative. Drug Metabolism and Drug Interactions, 2020, 35, .	0.3	1
153	El estigma de la esquizofrenia entre estudiantes no graduados de medicina y enfermerÃa. European Psychiatry (Ed EspaÃ±ola), 2003, 10, 132-133.	0.0	0
154	Editorial [Hot Topic: Pharmacogenetic and Pharmacogenomics (Guest Editors: A. LLerena and J. Licinio)]. Current Drug Targets, 2006, 7, 1639-1640.	2.1	0
155	Research Highlights. Pharmacogenomics, 2013, 14, 603-606.	1.3	0
156	Pharmacogenetic Studies of Suicide: Potential Relevance of Main Polymorphic CYPs and ABCB1. , 2016, , 415-433.		0
157	High prevalence ofCYP2D6ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations. Pharmacogenomics, 2020, 21, 1227-1236.	1.3	0
158	Relevance ofNR1I2variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital. Pharmacogenomics, 2021, 22, 983-996.	1.3	0
159	Editorial: CPPM 2013 Onward: Building a Socio-Technical GPS for Global Personalized Medicine â€“ A Welcome to Editors-In-Chief Adrian LLerena (Spain) and Ross A. McKinnon (Australia). Current Pharmacogenomics and Personalized Medicine, 2013, 11, 87-92.	0.2	0
160	Pharmacogenetics research in Brazil: a systematic review. Pharmacogenomics, 2022, 23, 263-275.	1.3	0
161	The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. Whatâ€™s next? An urgent clinical unmet need for patients. Drug Metabolism and Drug Interactions, 2020, 35, .	0.3	0